Mounjaro (Tirzepatide) Cost: 2026 Price, Savings & Coverage

How much does Mounjaro cost without insurance?

At full list price, a 28-day supply of Mounjaro costs $1,112.16, regardless of dose strength. Whether you're on the 2.5mg starting dose or the 15mg maximum, the per-pack price is identical. This pricing information comes directly from Eli Lilly's official pricing page at pricinginfo.lilly.com.

GoodRx and similar coupon services typically bring Mounjaro pens to approximately $900 to $1,100 at major pharmacy chains like CVS, Walgreens, and Walmart. The discount varies by pharmacy and coupon, so it's worth checking a few before filling a cash-pay prescription.

For most T2D patients, list price is not what they pay. Insurance coverage, savings cards, and LillyDirect self-pay all offer lower costs than list price. The sections below break down each route.

Mounjaro vs Zepbound: price comparison

Mounjaro and Zepbound contain the same compound (tirzepatide) at the same dose strengths, but they carry different FDA indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. The two list prices are within a few percent of each other. The practical gap is much larger on the insurance side: T2D coverage rules apply to Mounjaro NDCs, and weight-management rules apply to Zepbound. For a full comparison of both brands across all cost scenarios, see the Tirzepatide Cost Guide.

Does insurance cover Mounjaro for type 2 diabetes?

With a confirmed type 2 diabetes diagnosis, Mounjaro has a stronger insurance coverage case than most people expect. The FDA approved Mounjaro specifically for T2D in May 2022, so commercial insurers and Medicare treat it as a diabetes medication rather than a weight-loss drug. That's a meaningful distinction for coverage.

Coverage isn't automatic. Most plans require prior authorisation, and many impose step therapy requirements too. But the T2D indication gives your prescriber solid clinical grounds to satisfy both.

Mounjaro cost by route for T2D patients: LillyDirect self-pay, the savings card, and the annual Medicare Part D cap.

Prior authorisation and step therapy

Prior authorisation (PA) is the formal process where your insurer reviews whether Mounjaro is medically necessary before agreeing to cover it. For T2D patients, the typical PA requirements are:

• Documented T2D diagnosis with ICD-10 code E11.x in the chart.
• HbA1c level typically 7.0 to 7.5% or higher, demonstrating inadequate glycaemic control.
• Prior treatment documentation: many plans require evidence of trying and failing (or being intolerant of) metformin or another first-line agent.
• Step therapy: some plans require a documented failure of a generic GLP-1 or SGLT-2 inhibitor before approving a branded GLP-1 like Mounjaro.

Ask your prescriber's office to include specific HbA1c values, a medication history with dates, and a clinical necessity narrative in the PA submission. Detailed documentation is the biggest factor in approval rates.

What diagnosis code gets Mounjaro covered?

Mounjaro is FDA-approved only for type 2 diabetes. The relevant ICD-10 code is E11.x (type 2 diabetes mellitus, with various suffixes for complications and comorbidities). When your prescriber submits a PA or sends a prescription, this code signals to the insurer that Mounjaro is being used for its approved indication.

Prescribing Mounjaro off-label for weight loss without a T2D diagnosis, using an obesity code like E66.x instead, typically won't qualify for coverage under Mounjaro's NDC through commercial insurers or Medicare. The insurer may redirect the claim to Zepbound (which carries the weight-management indication) or deny it outright. The ICD-10 code isn't a technicality; it drives coverage decisions at most US commercial plans.

Mounjaro savings card for T2D patients

Eli Lilly's Mounjaro savings card lets eligible commercially insured patients pay as little as $25 per month for a 1 to 3-month supply. Key terms:

• Annual cap: $1,950 per calendar year in savings card benefits.
• Who qualifies: patients with active commercial insurance (private employer plan, ACA marketplace plan). Medicare and Medicaid patients are not eligible.
• How to apply: enroll directly through Eli Lilly's patient savings portal. The savings card is applied at the pharmacy counter; you do not need to submit claims separately.
• Stacking with insurance: the card covers the patient's out-of-pocket share after insurance pays its portion.

Medicare coverage for Mounjaro (type 2 diabetes)

Medicare covers Mounjaro under Part D specifically because it holds an FDA-approved type 2 diabetes indication. This is one of the clearest Medicare coverage distinctions in the GLP-1 class: Mounjaro (T2D) is covered, while Zepbound prescribed for weight loss alone is not covered by Part D itself. Medicare Part D excludes weight-loss-only medications by statute. Since July 1, 2026, a separate CMS demonstration, the Medicare GLP-1 Bridge, covers the Zepbound KwikPen, Wegovy and Foundayo for eligible Part D enrollees at a $50 copay through December 31, 2027. Mounjaro is not on the Bridge list, and people with type 2 diabetes are not eligible for the Bridge at all. Medicare.gov says their Part D plan might cover their GLP-1 instead (checked October 2, 2026).

A permanent Medicare expansion to cover GLP-1s for obesity has been debated, but it has not been enacted as of October 2026. The Bridge is temporary.

Mounjaro cost under Medicare: the annual Part D cap

Starting January 1, 2025, Medicare Part D introduced an annual out-of-pocket cap for prescription drug costs. It was $2,000 in 2025 and is indexed each year: $2,100 in 2026 and $2,400 in 2027 (CMS and Medicare.gov, checked October 2, 2026). For Mounjaro patients on Medicare, this changes the math considerably. With a list price around $1,080/month, standard Part D cost-sharing would previously have exposed beneficiaries to several thousand dollars per year. Under the new cap:

• Once your out-of-pocket drug costs reach the cap in a calendar year ($2,100 in 2026), you pay no cost sharing for covered Part D drugs for the rest of that year.
• For a drug priced near $1,080/month, a standard Part D design reaches the cap partway through the year (the 2026 deductible can be up to $615, then 25% coinsurance applies), depending on your plan's deductible and cost-sharing structure.
• The cap applies to all covered Part D drugs combined, not just Mounjaro.

What you pay before hitting the cap depends on your plan's tier placement and cost-sharing structure. Mounjaro is typically Tier 3 to Tier 4 (specialty) on Part D formularies, though this varies by plan. If you qualify for Extra Help (the Low Income Subsidy programme), cost-sharing can be much lower from the first fill.

Medicare Advantage plans

Medicare Advantage (Part C) plans include prescription drug coverage with their own formulary designs. Some MA plans negotiate tirzepatide coverage differently than stand-alone Part D plans, and tier placements vary. If you're on an MA plan, check your plan's formulary directly or use the CMS Medicare Plan Finder to compare. Don't assume the coverage terms from a stand-alone Part D plan apply to yours.

Other ways to lower your Mounjaro cost

The savings card and Medicare Part D aren't your only options. A few other routes can cut monthly costs for T2D patients.

LillyDirect self-pay pens

For cash-pay patients who cannot use the savings card, Eli Lilly sells Mounjaro directly through LillyDirect. As of October 2, 2026, LillyDirect lists the Mounjaro single-dose prefilled pen at a self-pay price starting at $499/month at every strength, from 2.5mg to 15mg. Mounjaro is not offered in vials on LillyDirect.

A valid prescription is required and terms apply. You may see lower LillyDirect prices quoted elsewhere: $299/month at 2.5mg, $399/month at 5mg and $449/month at 7.5 to 15mg (when refilled within 45 days). Those are Zepbound's self-pay prices. Zepbound is a separate tirzepatide product approved for weight management and obstructive sleep apnoea, not a cheaper way to buy Mounjaro. For the full breakdown of tirzepatide self-pay options, see the Tirzepatide Cost Guide.

Three main cost-reduction pathways for T2D patients: savings card, LillyDirect self-pay pen, and the Medicare Part D cap.

Optimise your dose

Mounjaro pricing is dose-agnostic both at list price and on LillyDirect, where every strength starts at $499/month (October 2026), so a lower dose does not lower the self-pay price. Your clinical goals and your prescriber's guidance should drive dose decisions, not price. Use the tirzepatide dosing calculator to model your steady-state drug level at any dose.

Insurance appeal rights for denied T2D claims

A denied prior authorisation isn't the end. T2D patients have solid clinical grounds for appeal:

• Ask your prescriber to include your HbA1c history, a list of prior diabetes medications with dates, and a clinical narrative explaining why Mounjaro fits your specific case.
• If the denial cites step therapy, check whether your prior medication history already satisfies it, or ask for a step therapy exception based on clinical necessity.
• Most insurers offer an expedited appeal timeline when delay could harm you. Your prescriber can request expedited review.

Medicaid coverage for T2D

Medicaid is federally required to cover Mounjaro for its FDA-approved T2D indication. With a confirmed T2D diagnosis, coverage is generally available through your state's programme, though prior authorisation and formulary requirements still apply. Coverage for obesity or weight management alone, without a T2D diagnosis, varies by state. Contact your state Medicaid programme to confirm your plan's terms.

Medicare's rules for GLP-1 drugs: what T2D patients need to know

The Medicare Coach breaks down Part D coverage rules for GLP-1 drugs, including why Mounjaro is covered for T2D but not for weight loss alone.

Source: The Medicare Coach (licensed Medicare expert). Duration: 4:26.

Is there a generic version of Mounjaro?

No. There's no FDA-approved generic or biosimilar version of Mounjaro as of 2026. Tirzepatide is a patented biologic manufactured exclusively by Eli Lilly. Generic entry requires patent expiry and a separate biosimilar regulatory pathway. Neither is expected for several years.

Compounded tirzepatide was widely available between 2022 and early 2025 under an FDA shortage exception, but that exception ended in February to March 2025 after FDA declared the shortage resolved. A federal court upheld the decision in May 2025. Bulk-compounded copies of Mounjaro are no longer legally permissible. For cash-pay patients, Lilly's own LillyDirect self-pay pen (from $499/month at every strength, October 2026) is the regulated route for Mounjaro itself.